Nilanjan Ghosh, MD, PhD, on New Avenues of CAR T Research in Lymphoma


The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed new CAR T-cell therapies being investigated for hematologic malignancies.

“CAR T-cell research is branching into novel antigens, dual targets, allogeneic CAR Ts, and methods to reduce the time needed for an autologous product to be developed. As we see more follow up with this over the next year or few years, we will learn more about them. It's very exciting research.”

As more chimeric antigen receptor (CAR) T-cell therapies come to market, clinicians are beginning to see the long-term impact of these treatments in the clinic. Currently approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies include lisocabtagene maraleucel (Breyanzi), axicabtagene cliolecleucel (Yescarta), brexucabtagene autoleucel (Tecartus) and ciltacabtagene autoleucel (Carvykti).

Nilanjan Ghosh, MD, PhD, chief of the lymphoma division and oncologist at Levine Cancer Institute, is seeing first-hand the impact of these cell therapies in hematologic malignancies. He has experience with these therapies on the clinic side and treats patients with malignancies such as lymphomas.

CGTLive spoke to Ghosh to learn more about new avenues of research with CAR T-cell therapies and what new advances may come up in the next few years. He discussed a few programs of note, including Novartis’ YTB323, Allogene’s ALLO501A, LV20.19, dual-targeted CAR T-cell therapies, and CD30-targeted CAR T-cell therapies.

Related Videos
Julie Kanter, MD
Mark Walters, MD
Ula V. Jurkunas, MD
Alfonso Sabater, MD, PhD, on Bringing Gene Therapy to Ophthalmology
Sharon Hesterlee, PhD
© 2023 MJH Life Sciences

All rights reserved.